Systemic thrombolysis in ischaemic stroke patients with COVID‐19

Objective Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID‐19 infection negatively modifies acute stroke procedures and, due to its pro‐coagulative effect, may potentially impact on IVT outcome. Thus, shor...

Full description

Saved in:
Bibliographic Details
Published inActa neurologica Scandinavica Vol. 145; no. 1; pp. 47 - 52
Main Authors Sobolewski, Piotr, Antecki, Jacek, Brola, Waldemar, Fudala, Małgorzata, Bieniaszewski, Leszek, Kozera, Grzegorz
Format Journal Article
LanguageEnglish
Published Denmark John Wiley & Sons, Inc 01.01.2022
John Wiley and Sons Inc
Subjects
Brain Ischemia - complications
Brain Ischemia - drug therapy
COVID-19
Fibrinolytic Agents - therapeutic use
functional outcome
Humans
Infections
Intravenous administration
intravenous thrombolysis
ischaemic stroke
Ischemia
Ischemic Stroke
Multivariate analysis
Original
Patients
Retrospective Studies
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Stroke
Stroke - complications
Stroke - drug therapy
t-Plasminogen activator
Thrombolysis
Thrombolytic drugs
Thrombolytic Therapy
Tissue Plasminogen Activator - therapeutic use
Treatment Outcome
COVID-19
ischaemic stroke
functional outcome
intravenous thrombolysis
Online AccessGet full text
ISSN0001-6314
1600-0404
1600-0404
DOI10.1111/ane.13520

Cover

Abstract Objective Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID‐19 infection negatively modifies acute stroke procedures and, due to its pro‐coagulative effect, may potentially impact on IVT outcome. Thus, short‐term efficacy and safety of IVT were compared in patients with and without evidence of SARS‐CoV‐2. Methods An observational, retrospective study included 70 patients with AIS, including 22 subjects (31%) with evidence of acute COVID‐19 infection, consecutively treated with IVT in 4 stroke centres between 15 September and 30 November 2020. Results Patients infected with COVID‐19 were characterized by higher median of National Institute of Health Stroke Scale (NIHSS) score (11.0 vs. 6.5; p < .01) and D‐dimers (870 vs. 570; p = .03) on admission, higher presence of pneumonia (47.8% vs. 12%; p < .01) and lower percentage of ‘minor stroke symptoms’ (NIHSS 1–5 pts.) (2% vs., 18%; p < .01). Hospitalizations were longer in patients with COVID‐19 than in those without it (17 vs. 9 days, p < .01), but impact of COVID‐19 infection on patients’ in‐hospital mortality or functional status on dismission has been confirmed neither in uni‐ or multivariate analysis. Conclusion SARS‐CoV‐2 infection prolongs length of stay in hospital after IVT, but does not influence in‐hospital outcome.
AbstractList Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID-19 infection negatively modifies acute stroke procedures and, due to its pro-coagulative effect, may potentially impact on IVT outcome. Thus, short-term efficacy and safety of IVT were compared in patients with and without evidence of SARS-CoV-2. An observational, retrospective study included 70 patients with AIS, including 22 subjects (31%) with evidence of acute COVID-19 infection, consecutively treated with IVT in 4 stroke centres between 15 September and 30 November 2020. Patients infected with COVID-19 were characterized by higher median of National Institute of Health Stroke Scale (NIHSS) score (11.0 vs. 6.5; p < .01) and D-dimers (870 vs. 570; p = .03) on admission, higher presence of pneumonia (47.8% vs. 12%; p < .01) and lower percentage of 'minor stroke symptoms' (NIHSS 1-5 pts.) (2% vs., 18%; p < .01). Hospitalizations were longer in patients with COVID-19 than in those without it (17 vs. 9 days, p < .01), but impact of COVID-19 infection on patients' in-hospital mortality or functional status on dismission has been confirmed neither in uni- or multivariate analysis. SARS-CoV-2 infection prolongs length of stay in hospital after IVT, but does not influence in-hospital outcome.
Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID-19 infection negatively modifies acute stroke procedures and, due to its pro-coagulative effect, may potentially impact on IVT outcome. Thus, short-term efficacy and safety of IVT were compared in patients with and without evidence of SARS-CoV-2.OBJECTIVEIntravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID-19 infection negatively modifies acute stroke procedures and, due to its pro-coagulative effect, may potentially impact on IVT outcome. Thus, short-term efficacy and safety of IVT were compared in patients with and without evidence of SARS-CoV-2.An observational, retrospective study included 70 patients with AIS, including 22 subjects (31%) with evidence of acute COVID-19 infection, consecutively treated with IVT in 4 stroke centres between 15 September and 30 November 2020.METHODSAn observational, retrospective study included 70 patients with AIS, including 22 subjects (31%) with evidence of acute COVID-19 infection, consecutively treated with IVT in 4 stroke centres between 15 September and 30 November 2020.Patients infected with COVID-19 were characterized by higher median of National Institute of Health Stroke Scale (NIHSS) score (11.0 vs. 6.5; p < .01) and D-dimers (870 vs. 570; p = .03) on admission, higher presence of pneumonia (47.8% vs. 12%; p < .01) and lower percentage of 'minor stroke symptoms' (NIHSS 1-5 pts.) (2% vs., 18%; p < .01). Hospitalizations were longer in patients with COVID-19 than in those without it (17 vs. 9 days, p < .01), but impact of COVID-19 infection on patients' in-hospital mortality or functional status on dismission has been confirmed neither in uni- or multivariate analysis.RESULTSPatients infected with COVID-19 were characterized by higher median of National Institute of Health Stroke Scale (NIHSS) score (11.0 vs. 6.5; p < .01) and D-dimers (870 vs. 570; p = .03) on admission, higher presence of pneumonia (47.8% vs. 12%; p < .01) and lower percentage of 'minor stroke symptoms' (NIHSS 1-5 pts.) (2% vs., 18%; p < .01). Hospitalizations were longer in patients with COVID-19 than in those without it (17 vs. 9 days, p < .01), but impact of COVID-19 infection on patients' in-hospital mortality or functional status on dismission has been confirmed neither in uni- or multivariate analysis.SARS-CoV-2 infection prolongs length of stay in hospital after IVT, but does not influence in-hospital outcome.CONCLUSIONSARS-CoV-2 infection prolongs length of stay in hospital after IVT, but does not influence in-hospital outcome.
Objective Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID‐19 infection negatively modifies acute stroke procedures and, due to its pro‐coagulative effect, may potentially impact on IVT outcome. Thus, short‐term efficacy and safety of IVT were compared in patients with and without evidence of SARS‐CoV‐2. Methods An observational, retrospective study included 70 patients with AIS, including 22 subjects (31%) with evidence of acute COVID‐19 infection, consecutively treated with IVT in 4 stroke centres between 15 September and 30 November 2020. Results Patients infected with COVID‐19 were characterized by higher median of National Institute of Health Stroke Scale (NIHSS) score (11.0 vs. 6.5; p < .01) and D‐dimers (870 vs. 570; p = .03) on admission, higher presence of pneumonia (47.8% vs. 12%; p < .01) and lower percentage of ‘minor stroke symptoms’ (NIHSS 1–5 pts.) (2% vs., 18%; p < .01). Hospitalizations were longer in patients with COVID‐19 than in those without it (17 vs. 9 days, p < .01), but impact of COVID‐19 infection on patients’ in‐hospital mortality or functional status on dismission has been confirmed neither in uni‐ or multivariate analysis. Conclusion SARS‐CoV‐2 infection prolongs length of stay in hospital after IVT, but does not influence in‐hospital outcome.
ObjectiveIntravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID‐19 infection negatively modifies acute stroke procedures and, due to its pro‐coagulative effect, may potentially impact on IVT outcome. Thus, short‐term efficacy and safety of IVT were compared in patients with and without evidence of SARS‐CoV‐2.MethodsAn observational, retrospective study included 70 patients with AIS, including 22 subjects (31%) with evidence of acute COVID‐19 infection, consecutively treated with IVT in 4 stroke centres between 15 September and 30 November 2020.ResultsPatients infected with COVID‐19 were characterized by higher median of National Institute of Health Stroke Scale (NIHSS) score (11.0 vs. 6.5; p < .01) and D‐dimers (870 vs. 570; p = .03) on admission, higher presence of pneumonia (47.8% vs. 12%; p < .01) and lower percentage of ‘minor stroke symptoms’ (NIHSS 1–5 pts.) (2% vs., 18%; p < .01). Hospitalizations were longer in patients with COVID‐19 than in those without it (17 vs. 9 days, p < .01), but impact of COVID‐19 infection on patients’ in‐hospital mortality or functional status on dismission has been confirmed neither in uni‐ or multivariate analysis.ConclusionSARS‐CoV‐2 infection prolongs length of stay in hospital after IVT, but does not influence in‐hospital outcome.
Author Bieniaszewski, Leszek
Fudala, Małgorzata
Brola, Waldemar
Antecki, Jacek
Sobolewski, Piotr
Kozera, Grzegorz
AuthorAffiliation 6 Medical Simulation Center Medical University of Gdańsk Gdańsk Poland
1 Department of Neurology and Stroke Unit in Sandomierz Jan Kochanowski University Kielce Poland
2 Collegium Medicum Jan Kochanowski University Kielce Poland
4 Department of Neurology and Stroke Unit Saint Lukas Hospital in Końskie Końskie Poland
3 Department of Neurology and Stroke Unit Regional Hospital in Kielce Kielce Poland
5 Department of Neurology and Stroke Unit Skłodowska‐Curie Hospital in Skarżysko‐Kamienna Skarżysko‐Kamienna Poland
AuthorAffiliation_xml – name: 1 Department of Neurology and Stroke Unit in Sandomierz Jan Kochanowski University Kielce Poland
– name: 3 Department of Neurology and Stroke Unit Regional Hospital in Kielce Kielce Poland
– name: 6 Medical Simulation Center Medical University of Gdańsk Gdańsk Poland
– name: 4 Department of Neurology and Stroke Unit Saint Lukas Hospital in Końskie Końskie Poland
– name: 2 Collegium Medicum Jan Kochanowski University Kielce Poland
– name: 5 Department of Neurology and Stroke Unit Skłodowska‐Curie Hospital in Skarżysko‐Kamienna Skarżysko‐Kamienna Poland
Author_xml – sequence: 1
  givenname: Piotr
  orcidid: 0000-0003-4646-1702
  surname: Sobolewski
  fullname: Sobolewski, Piotr
  email: piotrsobolewski@poczta.onet.pl
  organization: Jan Kochanowski University
– sequence: 2
  givenname: Jacek
  orcidid: 0000-0002-8667-7615
  surname: Antecki
  fullname: Antecki, Jacek
  organization: Regional Hospital in Kielce
– sequence: 3
  givenname: Waldemar
  orcidid: 0000-0002-7955-3454
  surname: Brola
  fullname: Brola, Waldemar
  organization: Saint Lukas Hospital in Końskie
– sequence: 4
  givenname: Małgorzata
  orcidid: 0000-0002-0884-8175
  surname: Fudala
  fullname: Fudala, Małgorzata
  organization: Skłodowska‐Curie Hospital in Skarżysko‐Kamienna
– sequence: 5
  givenname: Leszek
  orcidid: 0000-0001-6237-521X
  surname: Bieniaszewski
  fullname: Bieniaszewski, Leszek
  organization: Medical University of Gdańsk
– sequence: 6
  givenname: Grzegorz
  orcidid: 0000-0001-7704-2434
  surname: Kozera
  fullname: Kozera, Grzegorz
  organization: Medical University of Gdańsk
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34415051$$D View this record in MEDLINE/PubMed
BookMark eNp1UclOwzAQtRAIynLgB1AkLnAIjO2JnV6QoKwSggPL1UoThxqSuNgpqDc-gW_kS3BpQYDAl5H1Fr15s0zmG9toQtYp7NDwdrNG71CeMJgjHSoAYkDAedIBABoLTnGJLHt_H35MIi6SJY5IE0hohxxcjX2ra5NH7cDZum-rsTc-Mk1kfD7IPhDfOvugo2HWGt20Pno27SDqXd6eHb69vNLuKlkos8rrtdlcITfHR9e90_j88uSst38e5ygpxEyXJWVQSI5pwSEVMuFZXxTItUhSnYqcywKRUezSUqPIoashYIUsWVoWnK-QvanvcNSvdZGHLC6r1NCZOnNjZTOjfiKNGag7-6RSRJRdGgy2ZgbOPo60b1UdltRVFfqzI69YIjiyhHEZqJu_qPd25JqwnmICEpAihUmije-JvqJ81hsIu1NC7qz3TpcqN22o0U4CmkpRUJMDqhBAfRwwKLZ_KT5N_-LO3J9Npcf_E9X-xdFU8Q6HxqkK
CitedBy_id crossref_primary_10_1097_MD_0000000000039761
crossref_primary_10_3389_fneur_2022_984135
crossref_primary_10_1007_s11940_023_00747_6
crossref_primary_10_3389_fneur_2023_1239953
crossref_primary_10_3390_jcm11113004
crossref_primary_10_1155_2023_5931502
crossref_primary_10_1097_WCO_0000000000001146
crossref_primary_10_1007_s43440_022_00424_6
Cites_doi 10.1161/STR.0000000000000086
10.1016/S0140-6736(20)30566-3
10.1097/CM9.0000000000000824
10.1177/1747493018786616
10.1177/1747493020923234
10.1136/jnnp-2020-324927
10.1161/STR.0000000000000158
10.1161/01.STR.25.11.2220
10.1212/WNL.0000000000011885
10.1016/j.jstrokecerebrovasdis.2020.105344
10.1056/NEJMoa0804656
10.1177/1747493020972922
10.1016/j.jstrokecerebrovasdis.2015.03.045
10.1111/ene.14511
10.1007/s10072-020-04591-3
10.1161/01.STR.24.1.35
10.3389/fneur.2020.611504
10.1016/j.jocn.2020.05.006
10.1016/j.jstrokecerebrovasdis.2020.105569
10.1177/0271678X17695572
10.1016/j.jstrokecerebrovasdis.2019.104422
10.1136/jnnp-2020-324014
10.1016/j.ijantimicag.2020.105924
10.1016/j.jstrokecerebrovasdis.2020.105201
10.1161/STROKEAHA.120.031208
10.1161/01.STR.19.12.1497
10.1016/j.jstrokecerebrovasdis.2020.105435
10.1007/s12975-020-00818-9
10.1001/jama.2020.2648
ContentType Journal Article
Copyright 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Copyright © 2021 John Wiley & Sons A/S
Copyright_xml – notice: 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
– notice: 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
– notice: Copyright © 2021 John Wiley & Sons A/S
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
K9.
7X8
5PM
DOI 10.1111/ane.13520
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate SOBOLEWSKI et al
EISSN 1600-0404
EndPage 52
ExternalDocumentID PMC8444791
34415051
10_1111_ane_13520
ANE13520
Genre article
Journal Article
Observational Study
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
8FI
8FJ
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAJEY
AAKAS
AANHP
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABLJU
ABPVW
ABUWG
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCMX
ACCZN
ACGFS
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFEBI
AFFNX
AFGKR
AFKRA
AFPWT
AFZJQ
AHEFC
AHMBA
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BENPR
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
EAD
EAP
EAS
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPS
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FYBCS
FYUFA
FZ0
G-S
G.N
GODZA
H.X
H13
HF~
HMCUK
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PIMPY
PQQKQ
Q.N
Q11
QB0
R.K
RHX
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
UKHRP
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
AGQPQ
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7TK
K9.
7X8
5PM
ID FETCH-LOGICAL-c4710-2eff120d7348d3086753ab6d43e658e86c37d4421491fe46c09e03e6d7f28fd33
IEDL.DBID DR2
ISSN 0001-6314
1600-0404
IngestDate Thu Aug 21 18:30:32 EDT 2025
Sat Sep 27 16:48:22 EDT 2025
Fri Jul 25 20:57:05 EDT 2025
Thu Apr 03 07:06:12 EDT 2025
Tue Jul 01 01:27:29 EDT 2025
Thu Apr 24 22:50:05 EDT 2025
Wed Jan 22 16:27:07 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
ischaemic stroke
functional outcome
intravenous thrombolysis
Language English
License 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4710-2eff120d7348d3086753ab6d43e658e86c37d4421491fe46c09e03e6d7f28fd33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
The original article refers to the editorial paper by Bakola E and Giannopoulos S. (https://doi.org/10.1111/ane.13545)
ORCID 0000-0002-0884-8175
0000-0002-8667-7615
0000-0001-7704-2434
0000-0001-6237-521X
0000-0003-4646-1702
0000-0002-7955-3454
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8444791
PMID 34415051
PQID 2605076803
PQPubID 1036387
PageCount 0
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8444791
proquest_miscellaneous_2563425237
proquest_journals_2605076803
pubmed_primary_34415051
crossref_citationtrail_10_1111_ane_13520
crossref_primary_10_1111_ane_13520
wiley_primary_10_1111_ane_13520_ANE13520
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2022
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – month: 01
  year: 2022
  text: January 2022
PublicationDecade 2020
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Copenhagen
– name: Hoboken
PublicationTitle Acta neurologica Scandinavica
PublicationTitleAlternate Acta Neurol Scand
PublicationYear 2022
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 1993; 24
2020; 41
1988; 19
2020; 15
1994; 25
2020; 12
2020; 11
2020; 77
2020; 55
2020; 323
2021; 96
2021; 30
2018; 49
2021; 92
2015; 24
2021; 16
2021; 11
2017; 37
2020; 51
2020; 395
2019; 28
2020; 27
2008; 359
2020; 133
2012; 46
2016; 47
2018; 13
2020; 29
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
Wijeratne T (e_1_2_10_31_1) 2020; 12
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_30_1
e_1_2_10_29_1
Błażejewska‐Hyżorek B (e_1_2_10_18_1) 2012; 46
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 41
  start-page: 2325
  issue: 9
  year: 2020
  end-page: 2329
  article-title: A single‐centre experience of intravenous thrombolysis for stroke in COVID‐19 patients
  publication-title: Neurol Sci
– volume: 77
  start-page: 234
  year: 2020
  end-page: 236
  article-title: Intravenous thrombolysis for stroke in a COVID‐19 positive filipino patient, a case report
  publication-title: J Clin Neurosci
– volume: 16
  start-page: 137
  issue: 2
  year: 2021
  end-page: 149
  article-title: Stroke in COVID‐19: A systematic review and meta‐analysis
  publication-title: Int J Stroke
– volume: 30
  issue: 1
  year: 2021
  article-title: Characteristics and comparison of 32 COVID‐19 and non‐COVID‐19 ischemic strokes and historical stroke patients
  publication-title: J Stroke Cerebrovasc Dis
– volume: 24
  start-page: 1724
  issue: 8
  year: 2015
  end-page: 1729
  article-title: Stroke‐associated pneumonia in thrombolyzed patients: incidence and outcome
  publication-title: J Stroke Cerebrovasc Dis
– volume: 25
  start-page: 2220
  issue: 11
  year: 1994
  end-page: 2226
  article-title: Improved reliability of the NIH Stroke Scale using video training NINDS TPA stroke study group
  publication-title: Stroke
– volume: 37
  start-page: 3253
  issue: 9
  year: 2017
  end-page: 3261
  article-title: Inflammatory and metalloproteinases profiles predict three‐month poor outcomes in ischemic stroke treated with thrombolysis
  publication-title: J Cereb Blood Flow Metab
– volume: 51
  start-page: e254
  issue: 9
  year: 2020
  end-page: e258
  article-title: Characteristics and outcomes in patients with COVID‐19 and acute ischemic stroke: The global COVID‐19 stroke registry
  publication-title: Stroke
– volume: 13
  start-page: 949
  year: 2018
  end-page: 984
  article-title: Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018
  publication-title: Int J Stroke
– volume: 359
  start-page: 1317
  issue: 13
  year: 2008
  end-page: 1329
  article-title: Thrombolysis with alteplase 3 to 4,5 hours after acute ischaemic stroke
  publication-title: N Engl J Med
– volume: 96
  start-page: e2824
  year: 2021
  end-page: e2838
  article-title: SVIN COVID‐19 global stroke registry. Global impact of COVID‐19 on stroke care and IV thrombolysis
  publication-title: Neurology
– volume: 323
  start-page: 1239
  issue: 13
  year: 2020
  end-page: 1242
  article-title: Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention
  publication-title: JAMA
– volume: 27
  start-page: 2641
  issue: 12
  year: 2020
  end-page: 2645
  article-title: Thrombolysis and bridging therapy in patients with acute ischaemic stroke and Covid‐19
  publication-title: Eur J Neurol
– volume: 15
  start-page: 540
  issue: 5
  year: 2020
  end-page: 554
  article-title: Management of acute ischemic stroke in patients with COVID‐19 infection: Report of an international panel
  publication-title: Int J Stroke
– volume: 30
  year: 2021
  article-title: Patient characteristics and outcomes associated with decline in stroke volumes during the early COVID‐19 pandemic
  publication-title: J Stroke Cerebrovasc Dis
– volume: 55
  issue: 3
  year: 2020
  article-title: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and coronavirus disease‐2019 (COVID‐19): The epidemic and the challenges
  publication-title: Int J Antimicrob Agents
– volume: 29
  year: 2020
  article-title: The impact of COVID‐19 on acute ischemic stroke admissions: Analysis from a community‐based tertiary care center
  publication-title: J Stroke Cerebrovasc Dis
– volume: 24
  start-page: 35
  issue: 1
  year: 1993
  end-page: 41
  article-title: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment
  publication-title: Stroke
– volume: 133
  start-page: 1261
  issue: 11
  year: 2020
  end-page: 1267
  article-title: Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study
  publication-title: Chin Med J
– volume: 11
  year: 2021
  article-title: Acute stroke care in the with‐COVID‐19 Era: Experience at a comprehensive stroke center in Japan
  publication-title: Front Neurol
– volume: 12
  issue: 9
  year: 2020
  article-title: First australian case of good recovery of a COVID‐19 patient with severe neurological symptoms post prolonged hospitalization
  publication-title: Cureus
– volume: 395
  start-page: 1054
  issue: 10229
  year: 2020
  end-page: 1062
  article-title: Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study
  publication-title: Lancet
– volume: 49
  start-page: e46
  year: 2018
  end-page: e99
  article-title: 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ /American Stroke Association
  publication-title: Stroke
– volume: 11
  start-page: 322
  issue: 3
  year: 2020
  end-page: 325
  article-title: COVID‐19‐Related Stroke
  publication-title: Transl Stroke Res
– volume: 29
  issue: 11
  year: 2020
  article-title: Intravenous tPA for acute ischemic stroke in patients with COVID‐19
  publication-title: J Stroke Cerebrovasc Dis
– volume: 47
  start-page: 581
  issue: 2
  year: 2016
  end-page: 641
  article-title: American heart association stroke council and council on epidemiology and prevention. scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from the american heart association/american stroke association
  publication-title: Stroke
– volume: 28
  issue: 12
  year: 2019
  article-title: Novel definition of stroke good responders "predicts 90‐day outcome after thrombolysis"
  publication-title: J Stroke Cerebrovasc Dis
– volume: 92
  start-page: 226
  issue: 2
  year: 2021
  end-page: 228
  article-title: Intravenous thrombolysis for acute ischaemic stroke during COVID‐19 pandemic in Wuhan, China: a multicentre, retrospective cohort study
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 19
  start-page: 1497
  issue: 12
  year: 1988
  end-page: 1500
  article-title: Recovery of motor function after Stroke
  publication-title: Stroke
– volume: 46
  start-page: 3
  issue: 1
  year: 2012
  end-page: 78
  article-title: Postępowanie w udarze mózgu: wytyczne Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego
  publication-title: Neurol Neurochir Pol
– volume: 92
  start-page: 242
  issue: 3
  year: 2021
  end-page: 248
  article-title: SETICOS collaborators. Characteristics and outcomes of COVID‐19 associated stroke: a UK multicentre case‐control study
  publication-title: J Neurol Neurosurg Psychiatry 2020
– ident: e_1_2_10_26_1
  doi: 10.1161/STR.0000000000000086
– ident: e_1_2_10_3_1
  doi: 10.1016/S0140-6736(20)30566-3
– ident: e_1_2_10_29_1
  doi: 10.1097/CM9.0000000000000824
– volume: 12
  start-page: e10366
  issue: 9
  year: 2020
  ident: e_1_2_10_31_1
  article-title: First australian case of good recovery of a COVID‐19 patient with severe neurological symptoms post prolonged hospitalization
  publication-title: Cureus
– ident: e_1_2_10_7_1
  doi: 10.1177/1747493018786616
– ident: e_1_2_10_4_1
  doi: 10.1177/1747493020923234
– ident: e_1_2_10_5_1
  doi: 10.1136/jnnp-2020-324927
– ident: e_1_2_10_6_1
  doi: 10.1161/STR.0000000000000158
– ident: e_1_2_10_19_1
  doi: 10.1161/01.STR.25.11.2220
– ident: e_1_2_10_8_1
  doi: 10.1212/WNL.0000000000011885
– ident: e_1_2_10_9_1
  doi: 10.1016/j.jstrokecerebrovasdis.2020.105344
– ident: e_1_2_10_21_1
  doi: 10.1056/NEJMoa0804656
– ident: e_1_2_10_25_1
  doi: 10.1177/1747493020972922
– volume: 46
  start-page: 3
  issue: 1
  year: 2012
  ident: e_1_2_10_18_1
  article-title: Postępowanie w udarze mózgu: wytyczne Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego
  publication-title: Neurol Neurochir Pol
– ident: e_1_2_10_13_1
  doi: 10.1016/j.jstrokecerebrovasdis.2015.03.045
– ident: e_1_2_10_16_1
  doi: 10.1111/ene.14511
– ident: e_1_2_10_14_1
  doi: 10.1007/s10072-020-04591-3
– ident: e_1_2_10_22_1
  doi: 10.1161/01.STR.24.1.35
– ident: e_1_2_10_11_1
  doi: 10.3389/fneur.2020.611504
– ident: e_1_2_10_15_1
  doi: 10.1016/j.jocn.2020.05.006
– ident: e_1_2_10_10_1
  doi: 10.1016/j.jstrokecerebrovasdis.2020.105569
– ident: e_1_2_10_12_1
  doi: 10.1177/0271678X17695572
– ident: e_1_2_10_32_1
  doi: 10.1016/j.jstrokecerebrovasdis.2019.104422
– ident: e_1_2_10_23_1
  doi: 10.1136/jnnp-2020-324014
– ident: e_1_2_10_27_1
  doi: 10.1016/j.ijantimicag.2020.105924
– ident: e_1_2_10_17_1
  doi: 10.1016/j.jstrokecerebrovasdis.2020.105201
– ident: e_1_2_10_24_1
  doi: 10.1161/STROKEAHA.120.031208
– ident: e_1_2_10_20_1
  doi: 10.1161/01.STR.19.12.1497
– ident: e_1_2_10_30_1
  doi: 10.1016/j.jstrokecerebrovasdis.2020.105435
– ident: e_1_2_10_2_1
  doi: 10.1007/s12975-020-00818-9
– ident: e_1_2_10_28_1
  doi: 10.1001/jama.2020.2648
SSID ssj0012744
Score 2.3892405
Snippet Objective Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID‐19...
Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID-19 infection...
ObjectiveIntravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the core medical therapy of acute ischaemic stroke (AIS). COVID‐19...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 47
SubjectTerms Brain Ischemia - complications
Brain Ischemia - drug therapy
COVID-19
Fibrinolytic Agents - therapeutic use
functional outcome
Humans
Infections
Intravenous administration
intravenous thrombolysis
ischaemic stroke
Ischemia
Ischemic Stroke
Multivariate analysis
Original
Patients
Retrospective Studies
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Stroke
Stroke - complications
Stroke - drug therapy
t-Plasminogen activator
Thrombolysis
Thrombolytic drugs
Thrombolytic Therapy
Tissue Plasminogen Activator - therapeutic use
Treatment Outcome
Title Systemic thrombolysis in ischaemic stroke patients with COVID‐19
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fane.13520
https://www.ncbi.nlm.nih.gov/pubmed/34415051
https://www.proquest.com/docview/2605076803
https://www.proquest.com/docview/2563425237
https://pubmed.ncbi.nlm.nih.gov/PMC8444791
Volume 145
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6WPYRekjZtWrdpcUsPuXiRLFle01OepIVsoWTDHgLGlmS6pPWWePfSU35CfmN-SWbkB7vZBkpuhhlhW6MZzafHNwCfrWHKWqUCIbgOJDdxkIVJFEQ6ZyrnXEeMLgqfjdTpWH6bRJMefGnvwtT8EN2CG3mGi9fk4FleLTl5Vloq2hASXudCEW_-0Y-OOooT812d-vJACS4bViE6xdO1XJ2L1hLM9XOSy_mrm4BOtuCy_fT63MnVYDHPB_rvA1bHJ_7bc9hsElN_vx5JL6Bny23YOGu23l_CQc1tPtU-VVb4nc8cl4k_Lf1pRSfvSVLNr2dX1m-4WiufFnn9w-8XX4_ubm558grGJ8fnh6dBU4Ah0DhnsSC0RcFDZogBxwgEP4htslwZKSwmLnaotIiNlCGiLF5YqTRLLEOZiYtwWBghdqBfzkr7BnyRZDaKc4wG2mDOQDXOjVYsVlmBGNwMPdhrTZHqhp2cimT8SluUgn2Suj7x4FOn-qem5PiX0m5rz7Txyiol7EY7j0x48LEToz_RJgk2nS1QJ1IC41goYg9e1-bv3iIIfGIU8yBeGRidAnF1r0rK6U_H2T2UUsYJttxzdn_8w9P90bF7ePv_qu_gWUi3MtzK0C7059cL-x5zpXn-wTnFPVjiDs8
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hKpVeSoGWhmda9cAlyI4dZyP1QnloKewiIai4VFFiO-pqSxaxu5ee-An8Rn5JZ5yH2FKkqrdIM1YSj2c8D_sbgE_WMGWtUoEQXAeSmzjIwiQKIp0zlXOuI0YXhXt91b2UX6-iqzn43NyFqfAh2oQbaYaz16TglJB-pOVZaalrQ4gB-wtXnyOX6LwFj-KEfVc5vzxQgssaV4jO8bRDZ3ejJy7m05OSjz1YtwUdLcL35uOrkyfD3ekk39W__sB1_N-_ewOva9_U36sW0xLM2XIZXvbq6vsKfKngzQfap-YK1_nIwZn4g9IfjOnwPVHGk9vR0Po1XOvYpzyvv3_27fjg4e6eJ2_h8ujwYr8b1D0YAo3bFgtCWxQ8ZIZAcIzA-AfDmyxXRgqLvovtKC1iI2WIgRYvrFSaJZYhzcRF2CmMEO9gvhyV9j34IslsFOdoELRBt4HanButWKyyAsNw0_Fgp5FFqmuAcuqT8TNtAhWck9TNiQcfW9abCpXjb0wbjUDTWjHHKYVvVHxkwoMPLRlViuokOHQ0RZ5ICTRloYg9WK3k375FUPyJhsyDeGZltAwE1z1LKQc_HGx3R0oZJzhyxwn--Q9P9_qH7mHt31m3YaF70TtNT4_7J-vwKqRLGi5RtAHzk9up3UTXaZJvOQ35DT2jEu0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwEB4hkFAvpS2FhtI2VBy4BNmx42zEiQIraLtLVQHigBQltqOugCxidy-ceIQ-Y5-kM86P2C5IqLdIM1YSj-fPHn8DsGkNU9YqFQjBdSC5iYMsTKIg0jlTOec6YnRRuNdXh6fy63l0Pgc7zV2YCh-i3XAjzXD2mhT8xhQPlDwrLTVtCDFfX5AK3SRFRD9b7ChO0HdV7MsDJbisYYWojKcdOu2MZiLM2ULJhwGs80DdJbhovr0qPLncnozzbX33D6zjf_7cK3hZR6b-brWUXsOcLd_AYq8-e1-GLxW4-UD71FrhOh86MBN_UPqDEZXeE2U0vh1eWr8Gax35tMvr7x2fHe3_uf_Nk7dw2j042TsM6g4MgUanxYLQFgUPmSEIHCMw-8HkJsuVkcJi5GI7SovYSBlimsULK5VmiWVIM3ERdgojxArMl8PSvgNfJJmN4hzNgTYYNFCTc6MVi1VWYBJuOh5sNaJIdQ1PTl0yrtImTcE5Sd2cePC5Zb2pMDkeY1pv5JnWajlKKXmjo0cmPNhoyahQdEqCQ4cT5ImUQEMWitiD1Ur87VsEZZ9oxjyIpxZGy0Bg3dOUcvDLgXZ3pJRxgiO3nNyf_vB0t3_gHtaez_oJFn_sd9PvR_1v7-FFSDc03C7ROsyPbyf2A8ZN4_yj04-_-pYRnA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+thrombolysis+in+ischaemic+stroke+patients+with+COVID%E2%80%9019&rft.jtitle=Acta+neurologica+Scandinavica&rft.au=Sobolewski%2C+Piotr&rft.au=Antecki%2C+Jacek&rft.au=Brola%2C+Waldemar&rft.au=Fudala%2C+Ma%C5%82gorzata&rft.date=2022-01-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=0001-6314&rft.eissn=1600-0404&rft.volume=145&rft.issue=1&rft.spage=47&rft.epage=52&rft_id=info:doi/10.1111%2Fane.13520&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-6314&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-6314&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-6314&client=summon